{"public_id":"co_c5e5beb442c2b05a233b810003dc5c70","status":"active","merged_into_public_id":null,"resolved_public_id":"co_c5e5beb442c2b05a233b810003dc5c70","name":"market share by costs of targeted therapies","description":"The proportion of targeted therapy costs among total antineoplastic drug costs.","aliases":[],"types":["metric"],"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":3692938,"title":"Geographic Variations and Time Trends in Cancer Treatments in Taiwan","citation_count":7,"url":"https://sah.borca.ai/papers/3692938"}],"claims":[{"public_id":"cl_56a9c881839f4998a35d31b648c9a398","text":"Without considering the outer islands, the market share by prescription volume of targeted therapies increased almost 2-fold (1.84-1.90) and by costs increased 1.5-fold (1.26-1.61) between 2009 and 2012.","corpus_id":3692938,"url":"https://sah.borca.ai/claims/cl_56a9c881839f4998a35d31b648c9a398"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_c5e5beb442c2b05a233b810003dc5c70","url":"https://sah.borca.ai/concepts/co_c5e5beb442c2b05a233b810003dc5c70"}